Zimbabwe has turned down a significant US healthcare agreement valued at $367m (£272m) over five years because of the United States' request for sensitive data.
The decision became public following a government memo dated December was disclosed, which showed Head of State Emmerson Mnangagwa deemed the deal was "lopsided".
A government spokesman later explained that the US was seeking genetic material for scientific study and commercial gain but refused to guarantee the resulting advantages from future treatments.
"We are forced to start the challenging and unfortunate process of ending our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy said the United States had furnished over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has urged more dialogue to secure a deal agreeable to all parties so the country's critical HIV treatment initiative can proceed.
Wider Context
This rejection comes after a comparable situation in neighbouring Kenya, where a court halted a related health funding agreement following concerns were raised about the safety of citizens' health data.
Since resuming the presidency last year, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.
The agency had overseen assistance for the US government, but Trump argued its spending was "wasteful" and his government was seeking government-to-government agreements to enhance transparency and responsibility.
Based on reports, 16 African countries have to date signed these new health pacts, constituting over $18.3bn of fresh investment.
Specifics of the Rejected Deal
The funds for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We are confident this cooperation could have provided extraordinary benefits for Zimbabwean communities, particularly the 1.2 million presently receiving HIV treatment through American-funded initiatives," the Ambassador added.
However, official spokesman Nick Mangwana argued the arrangement was "unequal".
"Our nation was requested to share its biological resources and data indefinitely, with no corresponding assurance of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might result from that shared data," his statement read.
"In essence, our country would supply the basic resources for scientific discovery with no assurance that the end products would be accessible to our population should a new pandemic arise."
National Interest and Global Health
Mangwana further noted that the American exit from the World Health Organization (WHO) and its push of one-on-one health agreements were disrupting systems already established through the international health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing system designed to manage potential pandemics.
"This framework is intended to guarantee that when a nation contributes its samples, the resulting advantages – such as vaccines and treatments – are shared equitably, not monopolised solely by those with the funds to create them."
These objections over the US deal "should not be misconstrued as hostility towards the US," he added.
"We are open to ongoing dialogue with our US partners on how future co-operation might be structured in a manner that honours the independence and interests of each country."
Medical Community Response
A leading public health body stated it understood the government's concerns, but recommended that negotiations need to persist given that a large portion of the nation's Aids initiatives were funded by international support.
"If technical issues exist, including those involving information security or implementation frameworks, these can often be addressed through detailed discussion and mutually agreed protections," the group said.
The halted deal underscores the continuing challenges between receiving vital international aid and safeguarding local interests in an ever more interconnected world.